JP2010501163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501163A5 JP2010501163A5 JP2009524812A JP2009524812A JP2010501163A5 JP 2010501163 A5 JP2010501163 A5 JP 2010501163A5 JP 2009524812 A JP2009524812 A JP 2009524812A JP 2009524812 A JP2009524812 A JP 2009524812A JP 2010501163 A5 JP2010501163 A5 JP 2010501163A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- prlr
- amino acid
- extracellular domain
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 63
- 102100029000 Prolactin receptor Human genes 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 19
- 230000026731 phosphorylation Effects 0.000 claims description 15
- 238000006366 phosphorylation reaction Methods 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 12
- 238000010494 dissociation reaction Methods 0.000 claims description 12
- 230000005593 dissociations Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000012830 cancer therapeutic Substances 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 101100409237 Homo sapiens PRLR gene Proteins 0.000 claims description 6
- 101100409239 Mus musculus Prlr gene Proteins 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 101150009057 JAK2 gene Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 101150024075 Mapk1 gene Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 101100353203 Rattus norvegicus Prlr gene Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108091054455 MAP kinase family Proteins 0.000 claims description 2
- 102000043136 MAP kinase family Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229940071643 prefilled syringe Drugs 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000006711 vascular endothelial growth factor production Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 14
- 238000011275 oncology therapy Methods 0.000 claims 1
- 239000000463 material Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83864806P | 2006-08-18 | 2006-08-18 | |
| US60/838,648 | 2006-08-18 | ||
| US94636007P | 2007-06-26 | 2007-06-26 | |
| US60/946,360 | 2007-06-26 | ||
| PCT/US2007/076160 WO2008022295A2 (en) | 2006-08-18 | 2007-08-17 | Prlr-specific antibody and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274384A Division JP2013055959A (ja) | 2006-08-18 | 2012-12-17 | Ｐｒｌｒ特異的抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010501163A JP2010501163A (ja) | 2010-01-21 |
| JP2010501163A5 true JP2010501163A5 (cg-RX-API-DMAC7.html) | 2011-08-18 |
| JP5517619B2 JP5517619B2 (ja) | 2014-06-11 |
Family
ID=39083161
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524812A Expired - Fee Related JP5517619B2 (ja) | 2006-08-18 | 2007-08-17 | Ｐｒｌｒ特異的抗体およびその使用 |
| JP2012274384A Withdrawn JP2013055959A (ja) | 2006-08-18 | 2012-12-17 | Ｐｒｌｒ特異的抗体およびその使用 |
| JP2016074116A Withdrawn JP2016130250A (ja) | 2006-08-18 | 2016-04-01 | Ｐｒｌｒ特異的抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012274384A Withdrawn JP2013055959A (ja) | 2006-08-18 | 2012-12-17 | Ｐｒｌｒ特異的抗体およびその使用 |
| JP2016074116A Withdrawn JP2016130250A (ja) | 2006-08-18 | 2016-04-01 | Ｐｒｌｒ特異的抗体およびその使用 |
Country Status (37)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140081T1 (hr) * | 2006-08-18 | 2014-03-28 | Novartis Ag | Prlr-specifiäśna antitijela i njihova uporaba |
| EP2277044B1 (en) * | 2008-05-13 | 2015-06-17 | Genentech, Inc. | Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry |
| IN2012DN01920A (cg-RX-API-DMAC7.html) * | 2009-09-03 | 2015-07-24 | Schering Corp | |
| WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| CA2814652C (en) | 2010-10-13 | 2021-05-18 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
| JP5995851B2 (ja) * | 2010-10-18 | 2016-09-21 | メディアファーマ エス． アール． エル．Ｍｅｄｉａｐｈａｒｍａ Ｓ． Ｒ． Ｌ． | ＥｒｂＢ３結合抗体 |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN102250244A (zh) * | 2011-07-07 | 2011-11-23 | 南京医科大学 | 人源抗人催乳素受体抗体及其应用 |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| WO2013167669A1 (en) | 2012-05-10 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN102746402A (zh) * | 2012-07-09 | 2012-10-24 | 南京医科大学 | 全人源抗人催乳素受体单链抗体及其应用 |
| DK3489261T3 (da) | 2012-08-24 | 2020-12-14 | Univ California | Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase |
| US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| TW201920283A (zh) * | 2012-12-24 | 2019-06-01 | 美商艾伯維有限公司 | 催乳激素受體結合蛋白質及其用途 |
| CN105025925A (zh) * | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | 抗-催乳素受体抗体制剂 |
| US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| EP3088517B1 (en) * | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| US20180148514A1 (en) | 2014-10-02 | 2018-05-31 | City Of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EA201790834A1 (ru) | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| MY189159A (en) * | 2015-07-06 | 2022-01-29 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| ES2878188T3 (es) | 2015-07-29 | 2021-11-18 | Novartis Ag | Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| WO2017167217A1 (en) | 2016-04-01 | 2017-10-05 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| NZ748378A (en) * | 2016-04-14 | 2025-08-29 | Fred Hutchinson Cancer Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| JP7109007B2 (ja) | 2016-06-27 | 2022-07-29 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | がん治療の組み合わせ |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN110382534B (zh) | 2016-11-29 | 2023-05-09 | 里珍纳龙药品有限公司 | 治疗prlr阳性乳腺癌的方法 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| WO2018222722A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| IL322104A (en) | 2017-05-30 | 2025-09-01 | Bristol Myers Squibb Co | Treatment of lag-3 positive tumors |
| MY198804A (en) | 2017-06-07 | 2023-09-28 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3692048A4 (en) | 2017-08-30 | 2021-10-20 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
| WO2019175222A1 (en) | 2018-03-13 | 2019-09-19 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| CN112135624B (zh) | 2018-05-17 | 2024-07-19 | 瑞泽恩制药公司 | 抗cd63抗体、缀合物和其用途 |
| CA3100712A1 (en) * | 2018-05-17 | 2019-11-21 | Immunome, Inc. | Ch3 domain epitope tags |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| CN109627337B (zh) * | 2018-12-29 | 2023-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗prlr的单克隆抗体及其制备方法和应用 |
| US12233177B2 (en) | 2019-09-16 | 2025-02-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| JP6982129B2 (ja) * | 2020-04-27 | 2021-12-17 | 田中貴金属工業株式会社 | 抗水痘帯状疱疹ウイルス抗体、免疫学的測定方法及び免疫学的測定用装置 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4428150A1 (en) | 2023-03-07 | 2024-09-11 | Peptide Logic LLC | Antibody or antigen-binding fragment thereof |
| CN118834297A (zh) * | 2023-04-24 | 2024-10-25 | 深圳真实生物医药科技有限公司 | 泌乳素受体抗体及其用途 |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30985A (en) | 1860-12-18 | Thomas l | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| GB2056642B (en) | 1979-08-08 | 1983-05-11 | Dawson Int | Radio frequency drying of textile material |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| GB2118300B (en) * | 1982-02-12 | 1985-06-19 | Corning Glass Works | Method of immunoassay |
| DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US4975578A (en) * | 1989-04-17 | 1990-12-04 | The Research Foundation Of State University Of Ny | Method and apparatus for determining distribution of mass density |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| WO1993011266A1 (en) | 1991-12-05 | 1993-06-10 | Sloan-Kettering Institute For Cancer Research | Method for the detection of mutations and monoclonal lineages by analysis of rna conformation polymorphism(s) |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス，インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5807549A (en) | 1993-05-21 | 1998-09-15 | Research Corporation Technologies, Inc. | Lymphocyte chemoattractant factor and uses thereof |
| EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
| US5443953A (en) | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US6054287A (en) | 1994-05-27 | 2000-04-25 | Methodist Hospital Of Indiana, Inc. | Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6489145B1 (en) | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB9712818D0 (en) | 1996-07-08 | 1997-08-20 | Cambridge Antibody Tech | Labelling and selection of specific binding molecules |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20030044772A1 (en) | 1997-08-04 | 2003-03-06 | Applied Molecular Evolution [Formerly Ixsys] | Methods for identifying ligand specific binding molecules |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| AU764211C (en) | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DE60335794D1 (de) | 2002-03-29 | 2011-03-03 | Xoma Technology Ltd | Multigene vectoren und methoden für eine erhöhte expression von rekombinanten polypeptiden |
| CN1326879C (zh) | 2002-03-29 | 2007-07-18 | 先灵公司 | 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物 |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| BRPI0506726B8 (pt) * | 2004-01-07 | 2021-05-25 | Chiron Corp | anticorpo monoclonal específico para m-csf e usos deste |
| JP2008520204A (ja) * | 2004-11-15 | 2008-06-19 | イーライ リリー アンド カンパニー | 非アシル化グレリン抗体及びその治療への使用 |
| WO2006060769A2 (en) | 2004-12-03 | 2006-06-08 | Xoma Technology Ltd. | Methods and materials for expression of a recombinant protein |
| EP1910557A2 (en) * | 2005-04-07 | 2008-04-16 | Chiron Corporation | Cancer-related genes |
| WO2007051112A2 (en) * | 2005-10-24 | 2007-05-03 | Invitrogen Corporation | Serum prolactin binding protein in epithelial carcinoma |
| HRP20140081T1 (hr) * | 2006-08-18 | 2014-03-28 | Novartis Ag | Prlr-specifiäśna antitijela i njihova uporaba |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) * | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
-
2007
- 2007-08-17 HR HRP20140081TT patent/HRP20140081T1/hr unknown
- 2007-08-17 BR BRPI0715718-5A2A patent/BRPI0715718A2/pt not_active Application Discontinuation
- 2007-08-17 AR ARP070103686D patent/AR064801A1/es unknown
- 2007-08-17 US US11/840,267 patent/US7867493B2/en active Active
- 2007-08-17 MX MX2009001829A patent/MX2009001829A/es active IP Right Grant
- 2007-08-17 KR KR1020147004402A patent/KR20140033241A/ko not_active Ceased
- 2007-08-17 SI SI200731400T patent/SI2059535T1/sl unknown
- 2007-08-17 KR KR1020137005384A patent/KR101433544B1/ko not_active Expired - Fee Related
- 2007-08-17 PL PL07814191T patent/PL2059535T3/pl unknown
- 2007-08-17 WO PCT/US2007/076160 patent/WO2008022295A2/en not_active Ceased
- 2007-08-17 ME MEP-28/09A patent/ME00588A/xx unknown
- 2007-08-17 CA CA2661023A patent/CA2661023C/en not_active Expired - Fee Related
- 2007-08-17 CL CL200702412A patent/CL2007002412A1/es unknown
- 2007-08-17 EP EP18166185.1A patent/EP3415532A1/en not_active Withdrawn
- 2007-08-17 EA EA201201533A patent/EA201201533A1/ru unknown
- 2007-08-17 TW TW103102567A patent/TW201441262A/zh unknown
- 2007-08-17 RS RS20130576A patent/RS53092B/sr unknown
- 2007-08-17 AU AU2007285855A patent/AU2007285855B2/en not_active Ceased
- 2007-08-17 NZ NZ596834A patent/NZ596834A/xx not_active IP Right Cessation
- 2007-08-17 MY MYPI20090377A patent/MY145058A/en unknown
- 2007-08-17 AR ARP070103686A patent/AR062435A1/es unknown
- 2007-08-17 NZ NZ574138A patent/NZ574138A/en not_active IP Right Cessation
- 2007-08-17 PE PE2007001114A patent/PE20081214A1/es not_active Application Discontinuation
- 2007-08-17 CN CN2007800302847A patent/CN101611058B/zh not_active Expired - Fee Related
- 2007-08-17 JP JP2009524812A patent/JP5517619B2/ja not_active Expired - Fee Related
- 2007-08-17 EP EP07814191.8A patent/EP2059535B1/en active Active
- 2007-08-17 PT PT78141918T patent/PT2059535E/pt unknown
- 2007-08-17 TW TW096130566A patent/TWI454480B/zh not_active IP Right Cessation
- 2007-08-17 KR KR1020097003942A patent/KR101368596B1/ko not_active Expired - Fee Related
- 2007-08-17 EP EP15186855.1A patent/EP3018144A1/en not_active Withdrawn
- 2007-08-17 DK DK07814191.8T patent/DK2059535T3/da active
- 2007-08-17 ES ES07814191.8T patent/ES2444065T3/es active Active
- 2007-08-17 CA CA2932012A patent/CA2932012A1/en not_active Abandoned
- 2007-08-17 CN CN201310220338.3A patent/CN104098699A/zh active Pending
- 2007-08-17 EA EA200970210A patent/EA017851B1/ru not_active IP Right Cessation
- 2007-08-17 GE GEAP200711173A patent/GEP20125612B/en unknown
- 2007-08-17 EP EP11190591A patent/EP2423231A3/en not_active Withdrawn
-
2008
- 2008-12-31 TN TNP2008000548A patent/TNSN08548A1/en unknown
-
2009
- 2009-01-08 IL IL196397A patent/IL196397A/en active IP Right Grant
- 2009-01-15 ZA ZA2009/00351A patent/ZA200900351B/en unknown
- 2009-02-11 CU CU20090021A patent/CU23809A3/es not_active IP Right Cessation
- 2009-02-13 CR CR10612A patent/CR10612A/es unknown
- 2009-02-16 GT GT200900035A patent/GT200900035A/es unknown
- 2009-02-17 NI NI200900022A patent/NI200900022A/es unknown
- 2009-02-18 HN HN2009000379A patent/HN2009000379A/es unknown
- 2009-03-09 MA MA31703A patent/MA30762B1/fr unknown
- 2009-03-17 CO CO09027543A patent/CO6150194A2/es unknown
-
2010
- 2010-11-22 US US12/951,744 patent/US9005614B2/en active Active
-
2012
- 2012-12-17 JP JP2012274384A patent/JP2013055959A/ja not_active Withdrawn
-
2013
- 2013-01-17 IL IL224266A patent/IL224266A/en active IP Right Grant
-
2014
- 2014-01-30 CY CY20141100077T patent/CY1114904T1/el unknown
-
2015
- 2015-03-03 US US14/636,625 patent/US20150175705A1/en not_active Abandoned
-
2016
- 2016-04-01 JP JP2016074116A patent/JP2016130250A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010501163A5 (cg-RX-API-DMAC7.html) | ||
| KR102535195B1 (ko) | 항-코로나바이러스 항체 및 사용 방법 | |
| CN107001466B (zh) | 对淋巴细胞中抑制途径的中和 | |
| KR102047248B1 (ko) | 침식성 세포의 선택적 제거 | |
| KR20190044626A (ko) | 항-cd19 항체에 대한 항-이디오타입 항체 | |
| KR102866306B1 (ko) | 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도 | |
| JP2010500006A5 (cg-RX-API-DMAC7.html) | ||
| EP3283519A1 (en) | Methods of increasing strength and functionality with gdf8 inhibitors | |
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| KR20120099647A (ko) | ＣＤ１９ｘＣＤ３ 이중특이적 항체를 투여하는 투약 용법 | |
| JP2015178534A (ja) | 治療薬 | |
| KR20200027570A (ko) | 알파-시누클레인을 인식하는 인간화된 항체 | |
| KR20120056800A (ko) | 글루글루카곤 수용체에 대한 항체와 이의 사용 | |
| KR20200113228A (ko) | 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| EP3013860B1 (en) | Cb1 receptor antigen-binding proteins and uses thereof | |
| US20210009706A1 (en) | Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof | |
| KR20150013935A (ko) | 트랜스포터에 대한 항체 및 이의 용도 | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2009515827A5 (cg-RX-API-DMAC7.html) | ||
| WO2013012855A1 (en) | Apelin antigen-binding proteins and uses thereof | |
| JP2009544574A5 (cg-RX-API-DMAC7.html) | ||
| JP2009508532A5 (cg-RX-API-DMAC7.html) | ||
| WO2018115879A1 (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| JP2022527790A (ja) | 抗ｆｇｆ２３抗体分子 | |
| CN109890845A (zh) | 抗rankl抗体及其用途 |